After UCB’s Bimzelx scored five approvals just two years, the Belgian drugmaker has quickly made a blockbuster out of its ...

In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.

CAR-T therapies have changed the oncology space, but their cost and complexity have confined these treatments to specialized ...

A blockbuster drug is a best-selling medication earning over $1 billion annually. Learn about them and how they revolutionize ...

The expansion is expected to create 300 new jobs, including positions for engineers, scientists, manufacturing operators and lab technicians.

JNJ's diversified model, $32B R&D push and 48% stock surge in a year raise the stakes in its battle with ABBV for healthcare dominance.

Cardinal Health's analysis shows biosimilars are projected to strengthen cost savings and provider confidence across the healthcare ecosystem, with oncology rising in adoption and accessibility gains.

North Chicago officials, in a statement, said the 11,365-square-foot center will include a convenience store, video gaming lounge, drivers’ lounge with couches and showers, a full-service restaurant, ...

The new drug-pricing site is designed to help uninsured Americans ...

We came across a bullish thesis on Ultragenyx Pharmaceutical Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In ...

When prescription prices keep climbing, patients are forced into impossible decisions — skipping doses, delaying treatment or choosing between medication and other basic needs. For people with Crohn’s ...